The rationale for targeting CDK2, CDK4 and CDK6 has been solid since the discovery of these kinases almost 40 years ago. They sit at the bottom of the oncogenic signaling funnel, meaning that they are the final recipient and executioners of most of the oncogenic signals driving cancer cell proliferation. Cell surface receptors, like HER2…
25-plus years of Big Pharma megadeals
In February, Novo Holdings announced one of the largest M&A deals in recent memory with its plans to acquire Catalent, a leading contract drug manufacturer, for a cool $16.5 billion. The deal could accelerate production of Novo Nordisk’s blockbuster diabetes and weight-loss medications, Ozempic and Wegovy, given skyrocketing demand. But while the Novo-Catalent deal marks…